Osteoporosis treatment in postmenopausal women with pre-existing fracture

Taiwanese Journal of Obstetrics and Gynecology

Volumn 51, Issue 2, 2012, Pages 153-166

  Cheng, Ming Huei ^a,b   Chen, Jung Fu ^c   Fuh, Jong Ling ^a,d   Lee, Wen Ling ^e,f   Wang, Peng Hui ^a,d  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b ELI LILLY AND COMPANY   (United States)

^c CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^d TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^e CHENG HSIN GENERAL HOSPITAL   (Taiwan)

^f ORIENTAL INSTITUTE OF TECHNOLOGY   (Taiwan)

Author keywords

Bone; Fracture; Osteoporosis; Postmenopausal women

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CREATININE; DEOXYPYRIDINOLINE; ETIDRONIC ACID; IBANDRONIC ACID; OSTEOCALCIN; PARATHYROID HORMONE[1-34]; RALOXIFENE; RISEDRONIC ACID; SALCATONIN; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STRONTIUM RANELATE;

BACKACHE; BONE DENSITY; BONE REMODELING; BONE TURNOVER; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ESOPHAGITIS; ESOPHAGUS CANCER; GASTROINTESTINAL DISEASE; HOT FLUSH; HUMAN; JAW OSTEONECROSIS; KIDNEY DISEASE; LEG CRAMP; OSSIFICATION; OSTEOLYSIS; PATIENT COMPLIANCE; POSTMENOPAUSE OSTEOPOROSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHINITIS; STOMACH CANCER; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VERTEBRA FRACTURE;

BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; CALCITONIN; DIPHOSPHONATES; FEMALE; FRACTURES, BONE; HUMANS; ORGANOMETALLIC COMPOUNDS; OSTEOPOROSIS, POSTMENOPAUSAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TERIPARATIDE; THIOPHENES;

EID: 84863866572     PISSN: 10284559     EISSN: 18756263     Source Type: Journal    
DOI: 10.1016/j.tjog.2012.04.001     Document Type: Review

References (95)

1. Gass M., Dawson-Hughes B. Preventing osteoporosis-related fractures: an overview. Am J Med 2006, 119:S3-S11.
2. Becker D.J., Kilgore M.L., Morrisey M.A. The societal burden of osteoporosis. Curr Rheumatol Rep 2010, 12:186-191.
3. Kanis J.A., Johnell O. Requirements for DXA for the management of osteoporosis in Europe. Osteoporos Int 2005, 16:229-238.
4. Liu J.M., Ning G., Chen J.L. Osteoporotic fractures in Asia: risk factors and strategies for prevention. J Bone Miner Metab 2007, 25:1-5.
5. The Taiwanese Osteoporosis Association. Osteoporosis management- guideline and consensus. The Taiwan Osteoporosis Association. Published date: 27/03/2012. Access date: 16/06/2012. http://www.toa1997.org.tw/index.php?page_id=9bf31c7ff062936a96d3c8bd1f8f2ff3&mod=bulletin_edit&id=356.
6. Shao C.J., Hsieh Y.H., Tsai C.H., Lai K.A. A nationwide seven-year trend of hip fractures in the elderly population of Taiwan. Bone 2009, 44:125-129.
7. Lewiecki E.M. In the clinic. Ann Intern Med 2011, 155. Osteoporosis, ITC1-1-15.
8. Cheng M.H., Wang P.H. Uterine myoma: A condition amendable to medical therapy?. Expert Opinion Emerging Drugs 2008, 13:119-133.
9. Wang P.H., Su W.H., Sheu B.C., Liu W.M. Adenomyosis and its variance: adenomyoma and female fertility. Taiwan J Obstet Gynecol 2009, 48:232-238.
10. Wang P.H., Chao H.T., Chao K.C. Chemotherapy induced gonadotoxicity. Taiwan J Obstet Gynecol 2010, 49:1-2.
11. Wang P.H., Horng H.C., Cheng M.H., Chao H.T., Chao K.C. Standard and low-dose hormone therapy for postmenopausal women-Focus on the breast. Taiwan J Obstet Gynecol 2007, 46:127-134.
12. Lee W.L., Chao H.T., Wang P.H. Transdermal 17β-estradiol for preventing postmenopausal bone loss. J Chin Med Assoc 2007, 70:464-465.
13. Tsui K.H., Wang P.H. Borderline ovarian tumor and future fertility. J Chin Med Assoc 2011, 74:241-242.
14. Lee W.L., Liu W.M., Fuh J.L., Tsai Y.C., Shih C.C., Wang P.H. Basal follicle-stimulating hormone level changes after different types of uterine vessel occlusion in the management of uterine fibroids. Fertil Steril 2010, 94:2286-2290.
15. Chen C.H., Lee W.L., Chiu L.H., Sun H.D., Liu W.M., Wang P.H. A cohort study to evaluate the effectiveness of laparoscopic-guided local injection with etoposide in the management of women with unruptured tubal pregnancy. Fertil Steril 2011, 96:654-658.
16. Hodgson S.F., Watts N.B., Bilezikian J.P., Clarke B.L., Gray T.K., Harris D.W., et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003. Endocr Pract 2003, 9:544-564.
17. Nevitt M.C., Ross P.D., Palermo L., Musliner T., Genant H.K., Thompson D.E. Association of prevalent vertebral fractures, bone density, and alendronate treatment with incident vertebral fractures: effect of number and spinal location of fractures. The Fracture Intervention Trial Research Group. Bone 1999, 25:613-619.
18. Klotzbuecher C.M., Ross P.D., Landsman P.B., Abbott T.A., Berger M. Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 2000, 15:721-739.
19. Black D.M., Arden N.K., Palermo L., Pearson J., Cummings S.R. Prevalent vertebral deformities predict hip fractures and new vertebral deformities but not wrist fractures. Study of Osteoporotic Fractures Research Group. J Bone Miner Res 1999, 14:821-828.
20. Ross P.D., Davis J.W., Epstein R.S., Wasnich R.D. Pre-existing fractures and bone mass predict vertebral fracture incidence in women. Ann Intern Med 1991, 114:919-923.
21. Lindsay R., Silverman S.L., Cooper C., Hanley D.A., Barton I., Broy S.B., et al. Risk of new vertebral fracture in the year following a fracture. JAMA 2001, 285:320-323.
22. Ettinger B., Black D.M., Mitlak B.H., Knickerbocker R.K., Nickelsen T., Genant H.K., et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999, 282:637-645.
23. Ross P.D., Genant H.K., Davis J.W., Miller P.D., Wasnich R.D. Predicting vertebral fracture incidence from prevalent fractures and bone density among non-black, osteoporotic women. Osteoporos Int 1993, 3:120-126.
24. Reginster J., Minne H.W., Sorensen O.H., Hooper M., Roux C., Brandi M.L., et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 2000, 11:83-91.
25. Wynn R.L. Bisphosphonates, hypercalcemia of malignancy, and osteonecrosis of the jaw. Gen Dent 2005, 53:392-395.
26. Russell R.G.G. Bisphosphonates: mode of action and pharmacology. Pediatrics 2007, 119:S150-S162.
27. Lewis J.S., Jordan V.C. Selective estrogen receptor modulators (SERMs): mechanisms of anticarcinogenesis and drug resistance. Mutation Research 2005, 591:247-263.
28. Lee W.L., Chao H.T., Cheng M.H., Wang P.H. Rationale for using raloxifene to prevent both osteoporosis and breast cancer in postmenopausal women. Maturitas 2008, 60:92-107.
29. Lee W.L., Cheng M.H., Chao H.T., Wang P.H. The role of selective estrogen receptor modulator on breast cancer-from tamoxifen to raloxifene. Taiwan J Obstet Gynecol 2008, 47:24-31.
30. de Paula F.J., Rosen C.J. Back to the future: revisiting parathyroid hormone and calcitonin control of bone remodeling. Horm Metab Res 2010, 42:299-306.
31. Kallio D.M., Garant P.R., Minkin C. Ultrastructural effects of calcitonin on osteoclasts in tissue culture. J Ultrastruct Res 1972, 39:205-216.
32. Marie P.J. Strontium ranelate: a physiological approach for optimizing bone formation and resorption. Bone 2006, 38:S10-S14.
33. Bonnelye E., Chabadel A., Saltel F., Jurdic P. Dual effect of strontium ranelate: stimulation of osteoblast differentiation and inhibition of osteoclast formation and resorption in vitro. Bone 2008, 42:129-138.
34. Marie P.J., Hott M., Modrowski D., de Pollak C., Guillemain J., Deloffre P., Tsouderos Y. An uncoupling agent containing strontium prevents bone loss by depressing bone resorption and maintaining bone formation in estrogen-deficient rats. J Bone Miner Res 1993, 8:607-615.
35. Committee for Medicinal Products for Human Use. Protelos: EPAR-Scientific Discussion. European Medicines Agency. Published date: 21/11/2005. Access date: 16/06/2012. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000560/WC500045522.pdf.
36. Dempster D.W., Cosman F., Parisien M., Shen V. Anabolic actions of parathyroid hormone on bone. Endocr Res 1993, 14:690-709.
37. Hock J.M., Gera I. Effects of continuous and intermittent administration and inhibition of resorption on the anabolic response of bone to parathyroid hormone. J Bone Miner Res 1992, 7:65-72.
38. Black D.M., Cummings S.R., Karpf D.B., Cauley J.A., Thompson D.E., Nevitt M.C., et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996, 348:1535-1541.
39. Harris S.T., Watts N.B., Genant H.K., McKeever C.D., Hangartner T., Keller M., et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999, 282:1344-1352.
40. Melton L.J., Lane A.W., Cooper C., Eastell R., O'Fallon W.M., Riggs B.L. Prevalence and incidence of vertebral deformities. Osteoporos Int 1993, 3:113-119.
41. Genant H.K., Wu C.Y., van Kuijk C., Nevitt M.C. Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 1993, 8:1137-1148.
42. Delmas P.D., Recker R.R., Chesnut C.H., Skag A., Stakkestad J.A., Emkey R., et al. Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Osteoporos Int 2004, 15:792-798.
43. Chesnut C.H., Silverman S., Andriano K., Genant H., Gimona A., Harris S., et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med 2000, 109:267-276.
44. Meunier P.J., Roux C., Seeman E., Ortolani S., Badurski J.E., Spector T.D., et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004, 350:459-468.
45. Reginster J.Y., Felsenberg D., Boonen S., Diez-Perez A., Rizzoli R., Brandi M.L., et al. Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: results of a five-year, randomized, placebo-controlled trial. Arthritis Rheum 2008, 58:1687-1695.
46. Neer R.M., Arnaud C.D., Zanchetta J.R., Prince R., Gaich G.A., Reginster J.Y., et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001, 344:1434-1441.
47. Eriksen E.F., Melsen F., Sod E., Barton I., Chines A. Effects of long-term risedronate on bone quality and bone turnover in women with postmenopausal osteoporosis. Bone 2002, 31:620-625.
48. Ste-Marie L.G., Sod E., Johnson T., Chines A. Five years of treatment with risedronate and its effects on bone safety in women with postmenopausal osteoporosis. Calcif Tissue Int 2004, 75:469-476.
49. Arlot M., Meunier P.J., Boivin G., Haddock L., Tamayo J., Correa-Rotter R., et al. Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters. J Bone Miner Res 2005, 20:1244-1253.
50. Recker R.R., Marin F., Ish-Shalom S., Möricke R., Hawkins F., Kapetanos G., et al. Comparative effects of teriparatide and strontium ranelate on bone biopsies and biochemical markers of bone turnover in postmenopausal women with osteoporosis. J Bone Miner Res 2009, 24:1358-1368.
51. Sorensen O.H., Crawford G.M., Mulder H., Hosking D.J., Gennari C., Mellstrom D., et al. Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience. Bone 2003, 32:120-126.
52. Watts N.B., Josse R.G., Hamdy R.C., Hughes R.A., Manhart M.D., Barton I., et al. Risedronate prevents new vertebral fractures in postmenopausal women at high risk. J Clin Endocrinol Metab 2003, 88:542-549.
53. Chesnut C.H., Skag A., Christiansen C., Recker R., Stakkestad J.A., Hoiseth A., et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004, 19:1241-1249.
54. Francis R.M., Aspray T.J., Hide G., Sutcliffe A.M., Wilkinson P. Back pain in osteoporotic vertebral fractures. Osteoporos Int 2008, 19:895-903.
55. Marquis P., Roux C., de la Loge C., Diaz-Curiel M., Cormier C., Isaia G., et al. Strontium ranelate prevents quality of life impairment in post-menopausal women with established vertebral osteoporosis. Osteoporos Int 2008, 19:503-510.
56. Meunier P.J., Roux C., Ortolani S., Diaz-Curiel M., Compston J., Marquis P., et al. Effects of long-term strontium ranelate treatment on vertebral fracture risk in postmenopausal women with osteoporosis. Osteoporos Int 2009, 20:1663-1673.
57. Nevitt M.C., Chen P., Kiel D.P., Reginster J.Y., Dore R.K., Zanchetta J.R., et al. Reduction in the risk of developing back pain persists at least 30 months after discontinuation of teriparatide treatment: a meta-analysis. Osteoporos Int 2006, 17:1630-1637.
58. Langdahl B.L., Rajzbaum G., Jakob F., Karras D., Ljunggren O., Lems W.F., et al. Reduction in fracture rate and back pain and increased quality of life in postmenopausal women treated with teriparatide: 18-month data from the European Forsteo Observational Study (EFOS). Calcif Tissue Int 2009, 85:484-493.
59. Lyritis G., Marin F., Barker C., Pfeifer M., Farrerons J., Brixen K., et al. Back pain during different sequential treatment regimens of teriparatide: results from EUROFORS. Curr Med Res Opin 2010, 26:1799-1807.
60. Osteoporosis Quality of Life Study Group Measuring quality of life in women with osteoporosis. Osteoporos Int 1997, 7:478-487.
61. Silverman S.L., Minshall M.E., Shen W., Harper K.D., Xie S. Health-Related Quality of Life Subgroup of the Multiple Outcomes of Raloxifene Evaluation Study. The relationship of health-related quality of life to prevalent and incident vertebral fractures in postmenopausal women with osteoporosis: results from the Multiple Outcomes of Raloxifene Evaluation Study. Arthritis Rheum 2001, 44:2611-2619.
62. Barrett-Connor E., Ensrud K., Tosteson A.N., Varon S.F., Anthony M., Daizadeh N., et al. Design of the POSSIBLE USTM Study: postmenopausal women's compliance and persistence with osteoporosis medications. Osteoporos Int 2009, 20:463-472.
63. Woo C., Gao G., Wade S., Hochberg M.C. Gastrointestinal side effects in postmenopausal women using osteoporosis therapy: 1-year findings in the POSSIBLE US study. Curr Med Res Opin 2010, 26:1003-1009.
64. de Groen P.C., Lubbe D.F., Hirsch L.J., Daifotis A., Stephenson W., Freedholm D., et al. Esophagitis associated with the use of alendronate. N Engl J Med 1996, 335:1016-1021.
65. Ettinger B., Pressman A., Schein J. Clinic visits and hospital admissions for care of acid-related upper gastrointestinal disorders in women using alendronate for osteoporosis. Am J Manag Care 1998, 4:1377-1382.
66. Cardwell C.R., Abnet C.C., Cantwell M.M., Murray L.J. Exposure to oral bisphosphonates and risk of esophageal cancer. JAMA 2010, 304:657-663.
67. Wysowski D.K. Reports of esophageal cancer with oral bisphosphonate use. N Engl J Med 2009, 360:89-90.
68. Cartsos V.M., Zhu S., Zavras A.I. Bisphosphonate use and the risk of adverse jaw outcomes: a medical claims study of 714,217 people. J Am Dent Assoc 2008, 139:23-30.
69. Pazianas M., Blumentals W.A., Miller P.D. Lack of association between oral bisphosphonates and osteonecrosis using jaw surgery as a surrogate marker. Osteoporos Int 2008, 19:773-779.
70. Recker R.R., Lewiecki E.M., Miller P.D., Reiffel J. Safety of bisphosphonates in the treatment of osteoporosis. Am J Med 2009, 122:S22-S32.
71. Abrahamsen B. Adverse effects of bisphosphonates. Calcif Tissue Int 2010, 86:421-435.
72. Grosso A., Douglas I., Hingorani A., MacAllister R., Smeeth L. Oral bisphosphonates and risk of atrial fibrillation and flutter in women: a self-controlled case-series safety analysis. PLoS One 2009, 4. e4720.
73. Jamal S.A., Bauer D.C., Ensrud K.E., Cauley J.A., Hochberg M., Ishani A., et al. Alendronate treatment in women with normal to severely impaired renal function: an analysis of the Fracture Intervention Trial. J Bone Miner Res 2007, 22:503-508.
74. Watts N.B., Diab D.L. Long-term use of bisphosphonates in osteoporosis. J Clin Endocrinol Metab 2010, 95:1555-1565.
75. Shane E., Burr D., Ebeling P.R., Abrahamsen B., Adler R.A., Brown T.D., et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American society for bone and mineral research. J Bone Miner Res 2010, 25:2267-2294.
76. Wang P.H., Chao H.T. To switch or not to switch: should the study of tamoxifen and raloxifene (STAR) trial alter our decision?. Taiwan J Obstet Gynecol 2008, 47:372-374.
77. Cauley J.A., Norton L., Lippman M.E., Eckert S., Krueger K.A., Purdie D.W., et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Breast Cancer Res Treat 2001, 65:125-134.
78. Martino S., Cauley J.A., Barrett-Connor E., Powles T.J., Mershon J., Disch D., et al. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst 2004, 96:1751-1761.
79. Martino S., Disch D., Dowsett S.A., Keech C.A., Mershon J.L. Safety assessment of raloxifene over eight years in a clinical trial setting. Curr Med Res Opin 2005, 21:1441-1452.
80. Fleurence R.L., Iglesias C.P., Johnson J.M. The cost effectiveness of bisphosphonates for the prevention and treatment of osteoporosis: a structured review of the literature. Pharmacoeconomics 2007, 25:913-933.
81. Hiligsmann M., Vanoverberghe M., Neuprez A., Bruyère O., Reginster J.Y. Cost-effectiveness of strontium ranelate for the prevention and treatment of osteoporosis. Expert Rev Pharmacoecon Outcomes Res 2010, 10:359-366.
82. Hiligsmann M., Bruyère O., Reginster J.Y. Cost-effectiveness of strontium ranelate versus risedronate in the treatment of postmenopausal osteoporotic women aged over 75 years. Bone 2010, 46:440-446.
83. Ivergård M., Ström O., Borgström F., Burge R.T., Tosteson A.N., Kanis J. Identifying cost-effective treatment with raloxifene in postmenopausal women using risk algorithms for fractures and invasive breast cancer. Bone 2010, 47:966-974.
84. Stevenson M., Jones M.L., De Nigris E., Brewer N., Davis S., Oakley J. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis. Health Technol Assess 2005, 9:1-160.
85. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy Osteoporosis prevention, diagnosis, and therapy. JAMA 2001, 285:785-795.
86. Ammann P., Rizzoli R. Bone strength and its determinants. Osteoporos Int 2003, 14:S13-S18.
87. Hedlund L.R., Gallagher J.C. Increased incidence of hip fracture in osteoporotic women treated with sodium fluoride. J Bone Miner Res 1989, 4:223-225.
88. Meunier P.J., Sebert J.L., Reginster J.Y., Briancon D., Appelboom T., Netter P., et al. Fluoride salts are no better at preventing new vertebral fractures than calcium-vitamin D in postmenopausal osteoporosis: the FAVOStudy. Osteoporos Int 1998, 8:4-12.
89. Riggs B.L., Hodgson S.F., O'Fallon W.M., Chao E.Y., Wahner H.W., Muhs J.M., et al. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med 1990, 322:802-809.
90. Schnitzler C.M., Wing J.R., Gear K.A., Robson H.J. Bone fragility of the peripheral skeleton during fluoride therapy for osteoporosis. Clin Orthop Relat Res 1990, 261:268-275.
91. Cheng M.H., Wang S.J., Wang P.H., Fuh J.L. Attitudes toward menopause among middle-aged women: a community survey in an island of Taiwan. Maturitas 2005, 52:348-355.
92. Cheng M.H., Lee S.J., Wang S.J., Wang P.H., Fuh J.L. Does menopausal transition affect the quality of life? A longitudinal study of middle-aged women in Kinmen. Menopause 2007, 14:885-890.
93. Boonen S., Lips P., Bouillon R., Bischoff-Ferrari H.A., Vanderschueren D., Haentjens P. Need for additional calcium to reduce the risk of hip fracture with vitamin D supplementation: evidence from a comparative metaanalysis of randomized controlled trials. J Clin Endocrinol Metab 2007, 92:1415-1423.
94. Meacham S., Grayscott D., Chen J.J., Bergman C. Review of the dietary reference intake for calcium: where do we go from here?. Crit Rev Food Sci Nutr 2008, 48:378-384.
95. Dawson-Hughes B. National Osteoporosis Foundation Guide Committee. A revised clinician's guide to the prevention and treatment of osteoporosis. J Clin Endocrinol Metab 2008, 93:2463-2465.